Screening for NAFLD and its severity in type 2 diabetic patients: Value of magnetic resonance imaging and outstanding issues

磁共振成像 医学 价值(数学) 核磁共振 内科学 放射科 物理 计算机科学 机器学习
作者
Quentin Binet,Michel P. Hermans,Nicolas Lanthier
出处
期刊:Journal of Hepatology [Elsevier]
卷期号:78 (5): e166-e167 被引量:1
标识
DOI:10.1016/j.jhep.2022.12.004
摘要

A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetesJournal of HepatologyVol. 78Issue 3PreviewThere are limited prospective data on patients with type 2 diabetes mellitus (T2DM) specifically enrolled and systematically assessed for advanced fibrosis or cirrhosis due to non-alcoholic fatty liver disease (NAFLD). Therefore, we aimed to evaluate the prevalence of advanced fibrosis and cirrhosis in a prospectively recruited cohort of adults with T2DM. Full-Text PDF Reply to: “Screening for NAFLD and its severity in type 2 diabetic patients: Value of magnetic resonance imaging and outstanding issues”Journal of HepatologyVol. 78Issue 5PreviewWe thank Binet et al. for their comments regarding our recently published manuscript characterizing the prevalence of NAFLD, advanced fibrosis and cirrhosis in a prospectively recruited cohort of older adults with type 2 diabetes mellitus (T2DM).1,2 Binet and colleagues raise a few points which we seek to clarify. First, recruitment occurred through primary care and endocrinology clinics as well as IRB-approved advertisements directed at patients. Collaborators in primary care and endocrinology throughout the greater San Diego area were contacted and educated about the study. Full-Text PDF We read Ajmera et al.'s original manuscript[1]Ajmera V. Cepin S. Tesfai K. Hofflich H. Cadman K. Lopez S. et al.A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes.J Hepatol. 2023; 78: P471-P478https://doi.org/10.1016/j.jhep.2022.11.010Abstract Full Text Full Text PDF PubMed Scopus (7) Google Scholar with great interest. Screening for non-alcoholic fatty liver disease (NAFLD) is indeed crucial in the type 2 diabetes population because of the intricate links between insulin resistance and hepatic steatosis.[2]Binet Q. Loumaye A. Preumont V. Thissen J.P. Hermans M.P. Lanthier N. Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients: what do we know so far?.Acta Gastroenterol Belg. 2022; 85: 346-357https://doi.org/10.51821/85.2.9775Crossref PubMed Scopus (9) Google Scholar We were therefore looking forward to prospective studies in this area.[2]Binet Q. Loumaye A. Preumont V. Thissen J.P. Hermans M.P. Lanthier N. Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients: what do we know so far?.Acta Gastroenterol Belg. 2022; 85: 346-357https://doi.org/10.51821/85.2.9775Crossref PubMed Scopus (9) Google Scholar The great value of their analysis was the use of MRI-proton density fat fraction (PDFF) and elastography in the vast majority of patients, which allowed for optimal non-invasive assessment of the degree of steatosis and fibrosis[3]Park C.C. Nguyen P. Hernandez C. Bettencourt R. Ramirez K. Fortney L. et al.Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease.Gastroenterology. 2017; 152https://doi.org/10.1053/j.gastro.2016.10.026Abstract Full Text Full Text PDF Scopus (419) Google Scholar and to highlight advanced fibrosis (and even hepatocellular carcinoma) in patients with a low fibrosis-4 (FIB-4) score, for example.[1]Ajmera V. Cepin S. Tesfai K. Hofflich H. Cadman K. Lopez S. et al.A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes.J Hepatol. 2023; 78: P471-P478https://doi.org/10.1016/j.jhep.2022.11.010Abstract Full Text Full Text PDF PubMed Scopus (7) Google Scholar Although best suited for easy, large-scale screening, the FIB-4 score should indeed be used with caution in patients with diabetes.[4]Gracen L. Hayward K.L. Irvine K.M. Valery P.C. Powell E.E. Low accuracy of FIB-4 test to identify people with diabetes at low risk of advanced fibrosis.J Hepatol. 2022; 77: 1219-1221https://doi.org/10.1016/j.jhep.2022.06.016Abstract Full Text Full Text PDF PubMed Scopus (2) Google Scholar However, these results raise additional questions. First, did the selected patients represent a full sample of patients with type 2 diabetes? Over 7 years, with recruitment in primary care and endocrinology clinics, the authors only screened 524 patients. We therefore wonder whether study participation was proposed to all patients with type 2 diabetes seen during this period who met inclusion criteria. Secondly, the presence of one of the following criteria compatible with newly diagnosed diabetes was required as inclusion criteria (diabetes symptoms and plasma glucose ≥200 mg/dl or fasting plasma glucose ≥126 mg/dl or plasma glucose ≥200 mg/dl during a 75-g oral glucose tolerance test on two separate tests or HbA1c ≥6.5%). However, in the results section, 72% of patients were already treated with glucose-lowering drug(s). We therefore wonder whether this was a first diagnosis of NAFLD. Indeed, NAFLD is increasingly screened in endocrinology units, internal medicine and primary care, although progress is still needed with regard to screening. The authors provide the rate of diagnosed fibrosis and cancers, but do not mention the proportion of patients in whom NAFLD was likely already diagnosed and followed in hepatology clinic. In other words, it would be interesting to know how many new diagnoses (of NAFLD, cirrhosis and/or HCC) such a large-scale screening intervention would deliver. Third, we were surprised by the low prevalence of NAFLD in the study patients (65%), knowing the bidirectional links between NAFLD and insulin resistance.[5]Stefan N. Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes.Lancet Diabetes Endocrinol. 2022; 10: 284-296https://doi.org/10.1016/S2213-8587(22)00003-1Abstract Full Text Full Text PDF PubMed Scopus (107) Google Scholar We have two potential explanations for this. First, the degree of steatosis may decrease with advanced fibrosis or cirrhosis.[6]Tiniakos D.G. Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: histological diagnostic criteria and scoring systems.Eur J Gastroenterol Hepatol. 2010; 22: 643-650https://doi.org/10.1097/MEG.0b013e32832ca0cbCrossref PubMed Scopus (68) Google Scholar As elastography was performed in all patients, 38% of patients with less than 5% intrahepatic fat (thus not meeting the NAFLD criterion) had advanced fibrosis. Yet such advanced fibrosis was a late consequence of NAFLD. Secondly, an MRI-PDFF was not performed in all patients. Transient elastometry was used instead by measuring the controlled-attenuation parameter value and by choosing a cut-off of 288 dB/m, which can be considered as high, likely preventing inclusion of all patients with steatosis involving more than 5% of hepatocytes on histology.[7]de Lédinghen V. Vergniol J. Foucher J. Merrouche W. le Bail B. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.Liver Int. 2012; 32: 911-918https://doi.org/10.1111/j.1478-3231.2012.02820.xCrossref PubMed Scopus (292) Google Scholar Taken together, one can question the usefulness of hepatic fat quantification, which does not correlate with the complications of the disease[8]Angulo P. Kleiner D.E. Dam-Larsen S. Adams L.A. Bjornsson E.S. Charatcharoenwitthaya P. et al.Liver fibrosis, but No other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease.Gastroenterology. 2015; 149: 389-397.e10https://doi.org/10.1053/j.gastro.2015.04.043Abstract Full Text Full Text PDF PubMed Scopus (1782) Google Scholar and whose absence could falsely reassure the clinician, despite not ruling out advanced fibrosis.[1]Ajmera V. Cepin S. Tesfai K. Hofflich H. Cadman K. Lopez S. et al.A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes.J Hepatol. 2023; 78: P471-P478https://doi.org/10.1016/j.jhep.2022.11.010Abstract Full Text Full Text PDF PubMed Scopus (7) Google Scholar Finally, alcohol consumption can cause alcohol-related liver disease (ALD), and in real life, some patients with type 2 diabetes consume more than 20 g of alcohol per day (women) and 30 g per day (men). These patients were excluded from the study that focused on patients with NAFLD. An expert panel has proposed a definition with positive criteria for the diagnosis of metabolic dysfunction-associated fatty liver disease (MAFLD).[9]Eslam M. Newsome P.N. Sarin S.K. Anstee Q.M. Targher G. Romero-Gomez M. et al.A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement.J Hepatol. 2020; 73: 202-209https://doi.org/10.1016/j.jhep.2020.03.039Abstract Full Text Full Text PDF PubMed Scopus (1489) Google Scholar It would be interesting to know the proportion of patients with type 2 diabetes and regular excessive alcohol consumption who were excluded (thus presenting with MAFLD and superimposed ALD) and possibly to determine the impact of such consumption on liver disease severity,[10]Ntandja Wandji L.C. Gnemmi V. Mathurin P. Louvet A. Combined alcoholic and non-alcoholic steatohepatitis.JHEP Rep. 2020; 2https://doi.org/10.1016/j.jhepr.2020.100101Abstract Full Text Full Text PDF PubMed Scopus (34) Google Scholar assessed by these elegant MRI techniques. In conclusion, large prospective studies are awaited as screening for MAFLD is recommended in all patients with type 2 diabetes, whether elderly or not, or whether consuming alcohol or not. NL has a mandate as a Clinician Researcher from the FNRS, Belgium. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Please refer to the accompanying ICMJE disclosure forms for further details. Drafting of the manuscript: NL; critical revision and approval of the final manuscript: QB, MH, NL. The following are the supplementary data to this article: Download .pdf (.17 MB) Help with pdf files Multimedia component 1
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
hhzz完成签到,获得积分10
1秒前
1秒前
xhemers完成签到,获得积分10
1秒前
111发布了新的文献求助10
1秒前
2秒前
爱静静应助怡然的莫茗采纳,获得10
3秒前
4秒前
科研通AI5应助清秀的以云采纳,获得30
4秒前
李健的粉丝团团长应助xx采纳,获得10
6秒前
大豪子发布了新的文献求助30
6秒前
李繁蕊发布了新的文献求助10
6秒前
10秒前
10秒前
10秒前
10秒前
橘柚完成签到 ,获得积分10
11秒前
zmmmm发布了新的文献求助10
11秒前
领导范儿应助温言采纳,获得10
11秒前
思源应助OvO采纳,获得10
13秒前
迷糊发布了新的文献求助30
14秒前
LY发布了新的文献求助10
15秒前
zzz完成签到,获得积分10
15秒前
KimJongUn完成签到,获得积分10
15秒前
17秒前
17秒前
zy完成签到,获得积分10
18秒前
开心果子发布了新的文献求助10
18秒前
云痴子完成签到,获得积分10
19秒前
SciGPT应助粥粥采纳,获得10
19秒前
19秒前
19秒前
20秒前
苏源完成签到,获得积分10
20秒前
wu关闭了wu文献求助
20秒前
20秒前
21秒前
21秒前
22秒前
22秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Social media impact on athlete mental health: #RealityCheck 1020
Ensartinib (Ensacove) for Non-Small Cell Lung Cancer 1000
Unseen Mendieta: The Unpublished Works of Ana Mendieta 1000
Bacterial collagenases and their clinical applications 800
El viaje de una vida: Memorias de María Lecea 800
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3527928
求助须知:如何正确求助?哪些是违规求助? 3108040
关于积分的说明 9287614
捐赠科研通 2805836
什么是DOI,文献DOI怎么找? 1540070
邀请新用户注册赠送积分活动 716904
科研通“疑难数据库(出版商)”最低求助积分说明 709808